IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.

Immunotherapy is a beacon of hope in cancer's battle, but with a 10-20% response rate in solid tumors, its potential is untapped. Predicting patient responses to treatment, which current methods are ill-equipped for, is an urgent unmet medical need.

Our project stands for industrializing our analytically validated multiplexed protein-function based biomarker assay (IOO), currently TRL6, which is based on our proprietary bio-imaging technology.

Whilst scientifically validated, we need further clinical validation to obtain increased datasets required for regulatory certification for clinical deployment.

This assay could triple the efficacy of currently available immune-oncology treatments by accurately predicting patient response to immune checkpoint inhibitors - the basis of 90% of current immuno-oncology therapies. If successful, we will bring this transformative solution to hospitals worldwide. The upshot could be game-changing: doubling survival rates for high-prevalence, lethal tumors like lung cancer.